Supplemental Online Content

Augustin M, Lambert J, Zema C, et al. The Effect of Risankizumab on Patient-Reported Outcomes in Moderate to Severe Psoriasis: The UltIMMa-1 and UltIMMa-2 Randomized Clinical Trials. *JAMA Dermatol*. Published online October 14, 2020. doi: 10.1001/jamadermatol.2020.3617

eFigure. Consort Diagram

This supplemental material has been provided by the authors to give readers additional information about their work.



